Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Ipamorelin vs MK-677 (Ibutamoren)
An educational, source-based comparison of Ipamorelin and MK-677 (Ibutamoren) — how each peptide works, what it's researched for, and what to know before going deeper.
A selective ghrelin/GHS-R1a receptor agonist that stimulates GH release with minimal effect on cortisol, prolactin, or appetite — distinguishing it from older secretagogues like GHRP-6.
- Endogenous GH release without cortisol elevation
- Sleep quality and recovery markers
- Lean tissue retention in catabolic states
- • Generally well tolerated in research; long-term human safety data are limited.
- • Not FDA-approved.
- • Use in sport is prohibited (WADA).
Orally bioavailable non-peptide ghrelin mimetic.
Technically a small-molecule ghrelin receptor agonist (not a peptide), often grouped with peptide GH research. Orally bioavailable, it elevates GH and IGF-1 over 24 hours and increases appetite.
- GH/IGF-1 elevation in adults
- Lean mass and bone density in elderly
- Sleep quality (slow-wave sleep)
- • Not FDA-approved.
- • Insulin resistance and fluid retention reported.
- • Banned by WADA.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Ipamorelin | Ipamorelin, the first selective growth hormone secretagogue | European Journal of Endocrinology | 1998 | Characterized selectivity for GH release without affecting ACTH, cortisol, or prolactin. |
| MK-677 (Ibutamoren) | MK-677 increases GH and IGF-1 in elderly adults | Annals of Internal Medicine | 2008 | Two-year RCT showing sustained IGF-1 elevation and lean mass increase. |
Side-effect & safety grid
- Generally well tolerated in research; long-term human safety data are limited.
- Not FDA-approved.
- Use in sport is prohibited (WADA).
- Not FDA-approved.
- Insulin resistance and fluid retention reported.
- Banned by WADA.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Ipamorelin vs MK-677 (Ibutamoren) — Key differences
- Class: Ipamorelin is classified as Growth Hormone Axis, while MK-677 (Ibutamoren) is Growth Hormone Axis · Small Molecule.
- Primary research focus: Ipamorelin — endogenous gh release without cortisol elevation; MK-677 (Ibutamoren) — gh/igf-1 elevation in adults.
- Tag: Recovery · Sleep vs Growth hormone · Oral.